Manila Times Business
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its response package to questions received from its European Notified Body, GMED, following the successful completion of the Stage 1 and Stage 2 quality system and technical documentation assessments conducted by GMED as part of the MDR conformity assessment process for the Lumee® Oxygen Platform. The resp
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Genesis Wins Best Fixed Income Trading Solution
1h ago
Veyond Metaverse Closes Strategic Investment from Japan-Based Private Investor as Global Commercial Momentum Accelerates Across Its XR Medical Telepresence Platform
1h ago
EXL and Databricks expand collaboration to help enterprises build trusted data foundations for AI
1h ago
BlockchAIn Announces Preliminary Inclusion in Russell Microcap® Index
1h ago